title: Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011.
abstract: The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.
authors.affiliation: World Health Organization, Geneva, Switzerland. jordanm@who.int
authors.forename: M R
authors.initials: MR
authors.lastname: Jordan
authors.forename: D E
authors.initials: DE
authors.lastname: Bennett
authors.forename: M A
authors.initials: MA
authors.lastname: Wainberg
authors.forename: D
authors.initials: D
authors.lastname: Havlir
authors.forename: S
authors.initials: S
authors.lastname: Hammer
authors.forename: C
authors.initials: C
authors.lastname: Yang
authors.forename: L
authors.initials: L
authors.lastname: Morris
authors.forename: M
authors.initials: M
authors.lastname: Peeters
authors.forename: A M
authors.initials: AM
authors.lastname: Wensing
authors.forename: N
authors.initials: N
authors.lastname: Parkin
authors.forename: J B
authors.initials: JB
authors.lastname: Nachega
authors.forename: A
authors.initials: A
authors.lastname: Phillips
authors.forename: A
authors.initials: A
authors.lastname: De Luca
authors.forename: E
authors.initials: E
authors.lastname: Geng
authors.forename: A
authors.initials: A
authors.lastname: Calmy
authors.forename: E
authors.initials: E
authors.lastname: Raizes
authors.forename: P
authors.initials: P
authors.lastname: Sandstrom
authors.forename: C P
authors.initials: CP
authors.lastname: Archibald
authors.forename: J
authors.initials: J
authors.lastname: Perriëns
authors.forename: C M
authors.initials: CM
authors.lastname: McClure
authors.forename: S Y
authors.initials: SY
authors.lastname: Hong
authors.forename: J H
authors.initials: JH
authors.lastname: McMahon
authors.forename: N
authors.initials: N
authors.lastname: Dedes
authors.forename: D
authors.initials: D
authors.lastname: Sutherland
authors.forename: S
authors.initials: S
authors.lastname: Bertagnolio
mesh_terms: D044966:Anti-Retroviral Agents / Q000494:pharmacology*; D003906:Developing Countries; D024882:Drug Resistance, Viral; D014943:Global Health; D015658:HIV Infections / Q000188:drug therapy*; D006291:Health Policy; D006306:Health Surveys; D006801:Humans; D014944:World Health Organization
chemical_list: D044966:Anti-Retroviral Agents